Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25482068 | 0.90 | LMNA (1.00) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL25482072 | 0.84 | KMT2A (0.78) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL25481992 | 0.80 | SMN1; SMN2 (0.77) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL25482060 | 0.77 | KMT2A (0.74) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL25482053 | 0.77 | KMT2A (0.74) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL19079880 | 0.75 | USP2 (0.82) | TSHRSMN1; SMN2LMNAKMT2APKM | |
| SCHEMBL15503867 | 0.73 | USP2 (0.78) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL25482066 | 0.73 | KMT2A (0.71) | TSHRSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL13241787 | 0.73 | KMT2A (0.73) | SMN1; SMN2LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL25482016 | 0.72 | LMNA (0.82) | TSHRSMN1; SMN2LMNANPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | disclosed |
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | TFAM, FABP4, CPT2 | TSHR 1211/4885SMN1; SMN2 4396/4885LMNA 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.